Comparison tool

Eloralintide vs Cagrilintide side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

EloralintideCagrilintide

Share this peptide comparison

Property	Eloralintide	Cagrilintide
Category	Weight Loss	Weight Loss
Also known as	LY3841136	AM833, NN9838, CagriSema (combination)
FDA approved	No	No
Clinical status	Phase 3 recruiting; investigational. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Investigational phase 3 program, mainly through CagriSema; source reports an NDA submitted in Dec 2025 with FDA decision expected in Q4 2026. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Obesity and overweight	Weight loss, appetite control, combination therapy
How it works	Eloralintide is described as a selective amylin receptor agonist. In the supplied mechanism text, amylin/IAPP signaling involves receptor complexes formed by the calcitonin receptor with receptor-activity-modifying proteins, with activity in brainstem and hypothalamic regions involved in appetite control. The proposed effect is earlier satiety and reduced food intake. The source also states that lower nausea and vomiting versus injectable GLP-1 drugs was reported in Eloralintide trials, while lean-mass preservation remains unproven.	Cagrilintide is described as a long-acting amylin analog with activity across the amylin and calcitonin receptor family. The source reports signaling through amylin receptor complexes, including receptors formed by calcitonin receptors with RAMP proteins. Reported downstream effects include central satiety signaling, delayed gastric emptying, and moderation of meal-related glucagon increases. Mechanistic animal data in the source emphasize AMY1R and AMY3R pathways involving hindbrain regions such as the area postrema, nucleus of the solitary tract, and parabrachial nucleus. The molecule is described as a modified pramlintide-like 37-amino-acid analog with a fatty-diacid modification intended to extend exposure to about one week.
Typical dosing	Investigational study doses of 1-9 mg once weekly; no approved dose is established.	2.4 mg weekly · Once weekly
Research dosing	1-9 mg once weekly in the Phase 2 study · Once weekly · 48 weeks · Subcutaneous injection	2.4 mg weekly · Once weekly · Long-term / chronic use expected · Subcutaneous injection once weekly
Typical duration	48 weeks in the Phase 2 study	Long-term / chronic use expected
Administration	Subcutaneous injection	Subcutaneous injection once weekly
Timing	-	Any consistent time weekly With or without food
Evidence level	Clinical Trials	Clinical Trials
Possible side effects	Nausea (Source reports lower incidence than injectable GLP-1s and gives nausea at 8% in the Phase 1 summary.) Diarrhea Vomiting (Source gives vomiting at 4% in the Phase 1 summary.) +5 more Constipation Decreased appetite Abdominal discomfort Fatigue (Phase 2 topline summary describes fatigue among common mild-to-moderate adverse events.) Limited long-term safety data (Source states long-term safety and cardiovascular outcome results are not yet available.)	Nausea (Reported as common and usually temporary in the source.) Vomiting (Listed among reported gastrointestinal effects.) Diarrhea (Listed among reported gastrointestinal effects.) +8 more Constipation (Listed among reported gastrointestinal effects.) Abdominal pain (Reported in the source as a gastrointestinal adverse effect.) Injection site reactions (Reported in the source without additional severity detail.) Decreased appetite (Reported in the source; clinical relevance depends on study context.) Headache (Reported in the source without additional severity detail.) Dyspepsia (Reported in the source as a gastrointestinal symptom.) Gastrointestinal events in CagriSema trials (Source reports 79.6% affected, mostly mild to moderate.) Limited long-term safety data (Source notes ongoing trials and incomplete long-term safety characterization.)
Research summary	The supplied research summary reports a Phase 1 proof-of-concept trial published in 2026 by Eli Lilly that randomized 100 adults with obesity across five ascending dose groups. It describes dose-proportional pharmacokinetics and least-squares mean weight reductions from 2.6% to 11.3% at week 12, with nausea at 8% and vomiting at 4%. The source also reports Lilly topline Phase 2 results from November 2025 in 263 adults with obesity or overweight: at 48 weeks, all dose arms exceeded placebo, with mean weight loss ranging from about 9.5% at the lowest dose to 20.1% at 9 mg, compared with 0.4% on placebo. Other reported changes included waist circumference, blood pressure, lipid, and glycemic marker improvements. The source notes mild-to-moderate nausea and fatigue as common adverse events, and it cautions that full peer-reviewed Phase 2 data, head-to-head tirzepatide data, long-term safety, and cardiovascular outcome evidence were not yet available.	The supplied source describes cagrilintide as having controlled human evidence, including a 2021 phase 2 dose-finding trial in which once-weekly 4.5 mg cagrilintide was associated with about 10.8% mean body-weight loss over 26 weeks, compared with roughly 3% for placebo and about 9% for liraglutide 3.0 mg. The source also highlights phase 3 REDEFINE development for CagriSema in obesity and type 2 diabetes, with weight-loss results reported in the low-20% range for the combination. Gastrointestinal tolerability issues, especially nausea and vomiting, are described as prominent. As presented by the source, cagrilintide remains investigational rather than an approved standalone therapy.
References	PubMed PR Newswire +2 more Eli Lilly Investor Relations Eli Lilly	Source Source +3 more Source Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Eloralintide

Cagrilintide

Category

Weight Loss

Also known as

LY3841136

AM833, NN9838, CagriSema (combination)

FDA approved

Clinical status

Phase 3 recruiting; investigational.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Investigational phase 3 program, mainly through CagriSema; source reports an NDA submitted in Dec 2025 with FDA decision expected in Q4 2026.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Obesity and overweight

Weight loss, appetite control, combination therapy

How it works

Eloralintide is described as a selective amylin receptor agonist. In the supplied mechanism text, amylin/IAPP signaling involves receptor complexes formed by the calcitonin receptor with receptor-activity-modifying proteins, with activity in brainstem and hypothalamic regions involved in appetite control. The proposed effect is earlier satiety and reduced food intake. The source also states that lower nausea and vomiting versus injectable GLP-1 drugs was reported in Eloralintide trials, while lean-mass preservation remains unproven.

Cagrilintide is described as a long-acting amylin analog with activity across the amylin and calcitonin receptor family. The source reports signaling through amylin receptor complexes, including receptors formed by calcitonin receptors with RAMP proteins. Reported downstream effects include central satiety signaling, delayed gastric emptying, and moderation of meal-related glucagon increases. Mechanistic animal data in the source emphasize AMY1R and AMY3R pathways involving hindbrain regions such as the area postrema, nucleus of the solitary tract, and parabrachial nucleus. The molecule is described as a modified pramlintide-like 37-amino-acid analog with a fatty-diacid modification intended to extend exposure to about one week.

Typical dosing

Investigational study doses of 1-9 mg once weekly; no approved dose is established.

2.4 mg weekly · Once weekly

Research dosing

1-9 mg once weekly in the Phase 2 study · Once weekly · 48 weeks · Subcutaneous injection

2.4 mg weekly · Once weekly · Long-term / chronic use expected · Subcutaneous injection once weekly

Typical duration

48 weeks in the Phase 2 study

Long-term / chronic use expected

Administration

Subcutaneous injection

Subcutaneous injection once weekly

Timing

Any consistent time weekly

With or without food

Evidence level

Clinical Trials

Possible side effects

Nausea (Source reports lower incidence than injectable GLP-1s and gives nausea at 8% in the Phase 1 summary.)
Diarrhea
Vomiting (Source gives vomiting at 4% in the Phase 1 summary.)

+5 more

Constipation
Decreased appetite
Abdominal discomfort
Fatigue (Phase 2 topline summary describes fatigue among common mild-to-moderate adverse events.)
Limited long-term safety data (Source states long-term safety and cardiovascular outcome results are not yet available.)

Nausea (Reported as common and usually temporary in the source.)
Vomiting (Listed among reported gastrointestinal effects.)
Diarrhea (Listed among reported gastrointestinal effects.)

+8 more

Constipation (Listed among reported gastrointestinal effects.)
Abdominal pain (Reported in the source as a gastrointestinal adverse effect.)
Injection site reactions (Reported in the source without additional severity detail.)
Decreased appetite (Reported in the source; clinical relevance depends on study context.)
Headache (Reported in the source without additional severity detail.)
Dyspepsia (Reported in the source as a gastrointestinal symptom.)
Gastrointestinal events in CagriSema trials (Source reports 79.6% affected, mostly mild to moderate.)
Limited long-term safety data (Source notes ongoing trials and incomplete long-term safety characterization.)

Research summary

The supplied research summary reports a Phase 1 proof-of-concept trial published in 2026 by Eli Lilly that randomized 100 adults with obesity across five ascending dose groups. It describes dose-proportional pharmacokinetics and least-squares mean weight reductions from 2.6% to 11.3% at week 12, with nausea at 8% and vomiting at 4%. The source also reports Lilly topline Phase 2 results from November 2025 in 263 adults with obesity or overweight: at 48 weeks, all dose arms exceeded placebo, with mean weight loss ranging from about 9.5% at the lowest dose to 20.1% at 9 mg, compared with 0.4% on placebo. Other reported changes included waist circumference, blood pressure, lipid, and glycemic marker improvements. The source notes mild-to-moderate nausea and fatigue as common adverse events, and it cautions that full peer-reviewed Phase 2 data, head-to-head tirzepatide data, long-term safety, and cardiovascular outcome evidence were not yet available.

The supplied source describes cagrilintide as having controlled human evidence, including a 2021 phase 2 dose-finding trial in which once-weekly 4.5 mg cagrilintide was associated with about 10.8% mean body-weight loss over 26 weeks, compared with roughly 3% for placebo and about 9% for liraglutide 3.0 mg. The source also highlights phase 3 REDEFINE development for CagriSema in obesity and type 2 diabetes, with weight-loss results reported in the low-20% range for the combination. Gastrointestinal tolerability issues, especially nausea and vomiting, are described as prominent. As presented by the source, cagrilintide remains investigational rather than an approved standalone therapy.

References

PubMed PR Newswire

+2 more

Eli Lilly Investor Relations Eli Lilly

Source Source

+3 more

Source Source Source

Full profile

View Details